首页 > 最新文献

Acta Neuropsychiatrica最新文献

英文 中文
Network meta-analysis of the effectiveness of psychotherapies with or without medication for treating adult depression. 对有无药物治疗成人抑郁症的心理疗法效果进行网络荟萃分析。
IF 2.6 4区 医学 Q3 NEUROSCIENCES Pub Date : 2024-11-20 DOI: 10.1017/neu.2024.45
Mayumi Fukumori, Toshiaki Kikuchi, Yi Zhou, Satoshi Hattori, Takashi Kudo

Objective: To ascertain whether psychotherapies combined with medication are more efficacious than those without medication and determine which combinations yield the best results.

Methods: We conducted a network meta-analysis of randomised controlled trials (RCTs) comparing behavioural activation (BA), psychoanalytic/psychodynamic psychotherapy (DYN), interpersonal psychotherapy (IPT), individual face-to-face cognitive behavioural therapy (CBT (ftf)), group cognitive behavioural therapy (gCBT), and computerised or internet cognitive behavioural therapy (iCBT) with each other, or with treatment-as-usual (TAU) and wait list control (WLC) among adults formally diagnosed with depression. The psychotherapy arms were categorised as either psychotherapy alone or psychotherapy combined with medication (+ p). Treatment efficacy was assessed based on depression severity. We used a random-effects model to conduct a pairwise meta-analysis.

Results: A total of 100 RCTs with 9,873 participants were included. The most common treatment was CBT (ftf) alone. All treatment arms were compared with TAU. Most psychotherapies combined with medication were superior to psychotherapy alone. In the subgroup analyses according to the baseline severity of depression, most psychotherapies combined with medication were more effective than psychotherapy alone in moderate-to-severe depression, whereas in mild depression, such differences were not observed. Among psychotherapies with medication, gCBT + p was significantly more effective than TAU and other psychotherapies in both the main and subgroup analyses.

Conclusion: The efficacy of depression treatment varied depending on the severity of the depressive condition. Notably, gCBT + p was identified as the most effective approach for treating adult depression.

目的确定结合药物治疗的心理疗法是否比不结合药物治疗的心理疗法更有效,并确定哪种组合能产生最佳效果:我们对随机对照试验(RCT)进行了网络荟萃分析,比较了行为激活疗法(BA)、精神分析/心理动力学心理疗法(DYN)、人际心理疗法(IPT)、个人面对面认知行为疗法(CBT (ftf))、在被正式诊断为抑郁症的成年人中,将这些疗法与小组认知行为疗法(gCBT)、计算机化或互联网认知行为疗法(iCBT)、常规疗法(TAU)和候补对照组(WLC)进行比较。心理治疗组分为单独心理治疗组和心理治疗联合药物治疗组(+ p)。治疗效果根据抑郁症严重程度进行评估。我们采用随机效应模型进行了配对荟萃分析:结果:共纳入了 100 项 RCT,9873 名参与者。最常见的治疗方法是CBT(ftf)单独治疗。所有治疗方法都与 TAU 进行了比较。大多数结合药物治疗的心理疗法优于单独的心理疗法。在根据抑郁症基线严重程度进行的亚组分析中,对于中重度抑郁症患者,大多数结合药物治疗的心理疗法比单纯的心理疗法更有效,而对于轻度抑郁症患者,则没有观察到这种差异。在与药物治疗相结合的心理疗法中,gCBT + p在主分析和亚组分析中都明显比TAU和其他心理疗法更有效:结论:抑郁症的治疗效果因抑郁症的严重程度而异。值得注意的是,gCBT + p 被认为是治疗成人抑郁症最有效的方法。
{"title":"Network meta-analysis of the effectiveness of psychotherapies with or without medication for treating adult depression.","authors":"Mayumi Fukumori, Toshiaki Kikuchi, Yi Zhou, Satoshi Hattori, Takashi Kudo","doi":"10.1017/neu.2024.45","DOIUrl":"https://doi.org/10.1017/neu.2024.45","url":null,"abstract":"<p><strong>Objective: </strong>To ascertain whether psychotherapies combined with medication are more efficacious than those without medication and determine which combinations yield the best results.</p><p><strong>Methods: </strong>We conducted a network meta-analysis of randomised controlled trials (RCTs) comparing behavioural activation (BA), psychoanalytic/psychodynamic psychotherapy (DYN), interpersonal psychotherapy (IPT), individual face-to-face cognitive behavioural therapy (CBT (ftf)), group cognitive behavioural therapy (gCBT), and computerised or internet cognitive behavioural therapy (iCBT) with each other, or with treatment-as-usual (TAU) and wait list control (WLC) among adults formally diagnosed with depression. The psychotherapy arms were categorised as either psychotherapy alone or psychotherapy combined with medication (+ <i>p</i>). Treatment efficacy was assessed based on depression severity. We used a random-effects model to conduct a pairwise meta-analysis.</p><p><strong>Results: </strong>A total of 100 RCTs with 9,873 participants were included. The most common treatment was CBT (ftf) alone. All treatment arms were compared with TAU. Most psychotherapies combined with medication were superior to psychotherapy alone. In the subgroup analyses according to the baseline severity of depression, most psychotherapies combined with medication were more effective than psychotherapy alone in moderate-to-severe depression, whereas in mild depression, such differences were not observed. Among psychotherapies with medication, gCBT + <i>p</i> was significantly more effective than TAU and other psychotherapies in both the main and subgroup analyses.</p><p><strong>Conclusion: </strong>The efficacy of depression treatment varied depending on the severity of the depressive condition. Notably, gCBT + <i>p</i> was identified as the most effective approach for treating adult depression.</p>","PeriodicalId":48964,"journal":{"name":"Acta Neuropsychiatrica","volume":" ","pages":"1-15"},"PeriodicalIF":2.6,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142676488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phelan-McDermid syndrome-associated psychosis: a systematic review. 菲兰-麦克德米综合征相关精神病:系统回顾。
IF 2.6 4区 医学 Q3 NEUROSCIENCES Pub Date : 2024-11-20 DOI: 10.1017/neu.2024.46
Mark A Colijn

Objective: Phelan-McDermid syndrome is a rare genetic disorder characterised by various neurodevelopmental, medical, and psychiatric issues. Although bipolar disorder-like presentations and catatonia are particularly common, psychosis has also been reported but is less well described. As such, this systematic review sought to characterise the phenomenology of psychosis in Phelan-McDermid syndrome, clarify the association of psychotic symptoms with other neuropsychiatric features of the disorder, and describe antipsychotic treatment response.

Methods: A literature search was completed in July 2024 using PubMed and Scopus. Only English-language articles that reported the occurrence of psychotic symptoms in Phelan-McDermid syndrome were eligible for inclusion. 18 articles describing 35 individuals were included in the main analyses. Three additional articles of relevance are discussed separately, as they either provided limited clinical information or did not present data in a patient-specific manner.

Results: The average age of psychosis onset was ∼17 years, and 65% of individuals developed symptoms at or before age 15. ∼69% of individuals also experienced catatonia, ∼81% experienced mood symptoms, and 50% experienced both. Visual hallucinations were the most commonly reported psychotic symptom. Where reported, ∼76% of individuals exhibited at least a partial and/or temporary response to antipsychotic therapy.

Conclusion: Psychotic presentations in Phelan-McDermid syndrome may qualitatively differ from schizophrenia. Although numerous antipsychotics may be efficacious in the treatment of Phelan-McDermid syndrome-associated psychosis, this review most importantly highlights the paucity of available high-quality evidence to guide treatment decisions in this respect, and as such indicates the need for more reports to be published.

目的:菲兰-麦克德米综合征是一种罕见的遗传性疾病,其特征是各种神经发育、医疗和精神问题。虽然双相情感障碍样表现和紧张症特别常见,但精神病也有报道,但描述较少。因此,本系统综述试图描述菲兰-麦克德米综合征的精神病现象,阐明精神病症状与该疾病其他神经精神特征的关联,并描述抗精神病治疗的反应:于 2024 年 7 月使用 PubMed 和 Scopus 完成了文献检索。只有报道了 Phelan-McDermid 综合症患者出现精神病性症状的英文文章才有资格被纳入。主要分析包括 18 篇描述 35 名患者的文章。另外三篇相关文章单独进行了讨论,因为它们要么提供的临床信息有限,要么没有以特定患者的方式提供数据:精神病患者的平均发病年龄为 17 岁,65% 的患者在 15 岁或 15 岁之前出现症状。视幻觉是最常见的精神病症状。76%(13/17)的患者至少对抗精神病治疗有部分和/或暂时的反应:结论:Phelan-McDermid综合征的精神病表现可能与精神分裂症有本质区别。尽管许多抗精神病药物对治疗与菲兰-麦克德米综合征相关的精神病可能有效,但本综述最重要的是强调了在这方面用于指导治疗决策的高质量证据的匮乏,因此表明需要发表更多的报告。
{"title":"Phelan-McDermid syndrome-associated psychosis: a systematic review.","authors":"Mark A Colijn","doi":"10.1017/neu.2024.46","DOIUrl":"10.1017/neu.2024.46","url":null,"abstract":"<p><strong>Objective: </strong>Phelan-McDermid syndrome is a rare genetic disorder characterised by various neurodevelopmental, medical, and psychiatric issues. Although bipolar disorder-like presentations and catatonia are particularly common, psychosis has also been reported but is less well described. As such, this systematic review sought to characterise the phenomenology of psychosis in Phelan-McDermid syndrome, clarify the association of psychotic symptoms with other neuropsychiatric features of the disorder, and describe antipsychotic treatment response.</p><p><strong>Methods: </strong>A literature search was completed in July 2024 using PubMed and Scopus. Only English-language articles that reported the occurrence of psychotic symptoms in Phelan-McDermid syndrome were eligible for inclusion. 18 articles describing 35 individuals were included in the main analyses. Three additional articles of relevance are discussed separately, as they either provided limited clinical information or did not present data in a patient-specific manner.</p><p><strong>Results: </strong>The average age of psychosis onset was ∼17 years, and 65% of individuals developed symptoms at or before age 15. ∼69% of individuals also experienced catatonia, ∼81% experienced mood symptoms, and 50% experienced both. Visual hallucinations were the most commonly reported psychotic symptom. Where reported, ∼76% of individuals exhibited at least a partial and/or temporary response to antipsychotic therapy.</p><p><strong>Conclusion: </strong>Psychotic presentations in Phelan-McDermid syndrome may qualitatively differ from schizophrenia. Although numerous antipsychotics may be efficacious in the treatment of Phelan-McDermid syndrome-associated psychosis, this review most importantly highlights the paucity of available high-quality evidence to guide treatment decisions in this respect, and as such indicates the need for more reports to be published.</p>","PeriodicalId":48964,"journal":{"name":"Acta Neuropsychiatrica","volume":" ","pages":"1-10"},"PeriodicalIF":2.6,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142676865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A randomised study and an extension study of brexpiprazole in patients with borderline personality disorder. 针对边缘型人格障碍患者的布雷克吡唑随机研究和扩展研究。
IF 2.6 4区 医学 Q3 NEUROSCIENCES Pub Date : 2024-11-19 DOI: 10.1017/neu.2024.31
Brian Rothman, Claudette Brewer, Denise Chang, Mary Hobart, Nanco Hefting, Robert D McQuade, Jon E Grant

Objective: No drugs are currently approved for the treatment of borderline personality disorder (BPD). These studies (a randomised study and its open-label extension) aimed to evaluate the efficacy, safety and tolerability of brexpiprazole for the treatment of BPD.

Methods: The Phase 2, multicentre, randomised, double-blind, placebo-controlled, parallel-group study enrolled adult outpatients with BPD. After a 1-week placebo run-in, patients were randomised 1:1 to brexpiprazole 2-3 mg/day (flexible dose) or placebo for 11 weeks. The primary endpoint was change in Zanarini Rating Scale for BPD total score from randomisation (Week 1) to Week 10 (timing of randomisation and endpoint blinded to investigators and patients). The Phase 2/3, multicentre, open-label extension study enrolled patients who completed the randomised study; all patients received brexpiprazole 2-3 mg/day (flexible dose) for 12 weeks. Safety assessments included treatment-emergent adverse events (TEAEs).

Results: Brexpiprazole was not statistically significantly different from placebo on the primary endpoint of the randomised study (N = 324 randomised; N = 110 analysed per treatment group; least squares mean difference -1.02; 95% confidence limits -2.75, 0.70; p = 0.24). Numerical efficacy advantages for brexpiprazole were observed at other time points. The most common TEAE in the randomised study was akathisia (brexpiprazole, 14.0%; placebo, 1.2%); data from the open-label study (N = 199 analysed) suggested that TEAEs were transient.

Conclusion: The primary endpoint of the randomised study was not met. Further research on brexpiprazole in BPD is warranted based on possible efficacy signals at other time points and its safety profile.ClinicalTrials.gov identifiers: NCT04100096, NCT04186403. Funding: Otsuka, Lundbeck.

目的:目前尚无药物被批准用于治疗边缘型人格障碍(BPD)。这些研究(一项随机研究及其开放标签延伸研究)旨在评估布来哌唑治疗边缘型人格障碍的疗效、安全性和耐受性:2期多中心、随机、双盲、安慰剂对照、平行组研究招募了患有BPD的成年门诊患者。经过1周的安慰剂试验后,患者按1:1的比例随机接受布来哌唑2-3毫克/天(灵活剂量)或安慰剂治疗,为期11周。主要终点为从随机化(第1周)到第10周扎纳里尼BPD评定量表总分的变化(随机化时间和终点对研究人员和患者保密)。这项2/3期、多中心、开放标签扩展研究招募了完成随机研究的患者;所有患者都接受了为期12周、每天2-3毫克(灵活剂量)的布来哌唑治疗。安全性评估包括治疗突发不良事件(TEAEs):在随机研究的主要终点上,布雷克普拉唑与安慰剂没有显著的统计学差异(随机人数=324人;每个治疗组分析人数=110人;最小二乘法均值差异-1.02;95%置信区间-2.75,0.70;P=0.24)。在其他时间点也观察到了布来哌唑的疗效优势。随机研究中最常见的TEAE是肌无力(布来哌唑,14.0%;安慰剂,1.2%);开放标签研究(分析人数=199)的数据表明,TEAE是短暂的:结论:随机研究的主要终点没有达到。基于其他时间点可能出现的疗效信号及其安全性,有必要进一步研究布来哌唑在BPD中的应用:NCT04100096、NCT04186403。资助:大冢制药、灵北制药。
{"title":"A randomised study and an extension study of brexpiprazole in patients with borderline personality disorder.","authors":"Brian Rothman, Claudette Brewer, Denise Chang, Mary Hobart, Nanco Hefting, Robert D McQuade, Jon E Grant","doi":"10.1017/neu.2024.31","DOIUrl":"10.1017/neu.2024.31","url":null,"abstract":"<p><strong>Objective: </strong>No drugs are currently approved for the treatment of borderline personality disorder (BPD). These studies (a randomised study and its open-label extension) aimed to evaluate the efficacy, safety and tolerability of brexpiprazole for the treatment of BPD.</p><p><strong>Methods: </strong>The Phase 2, multicentre, randomised, double-blind, placebo-controlled, parallel-group study enrolled adult outpatients with BPD. After a 1-week placebo run-in, patients were randomised 1:1 to brexpiprazole 2-3 mg/day (flexible dose) or placebo for 11 weeks. The primary endpoint was change in Zanarini Rating Scale for BPD total score from randomisation (Week 1) to Week 10 (timing of randomisation and endpoint blinded to investigators and patients). The Phase 2/3, multicentre, open-label extension study enrolled patients who completed the randomised study; all patients received brexpiprazole 2-3 mg/day (flexible dose) for 12 weeks. Safety assessments included treatment-emergent adverse events (TEAEs).</p><p><strong>Results: </strong>Brexpiprazole was not statistically significantly different from placebo on the primary endpoint of the randomised study (<i>N</i> = 324 randomised; <i>N</i> = 110 analysed per treatment group; least squares mean difference -1.02; 95% confidence limits -2.75, 0.70; <i>p</i> = 0.24). Numerical efficacy advantages for brexpiprazole were observed at other time points. The most common TEAE in the randomised study was akathisia (brexpiprazole, 14.0%; placebo, 1.2%); data from the open-label study (<i>N</i> = 199 analysed) suggested that TEAEs were transient.</p><p><strong>Conclusion: </strong>The primary endpoint of the randomised study was not met. Further research on brexpiprazole in BPD is warranted based on possible efficacy signals at other time points and its safety profile.ClinicalTrials.gov identifiers: NCT04100096, NCT04186403. Funding: Otsuka, Lundbeck.</p>","PeriodicalId":48964,"journal":{"name":"Acta Neuropsychiatrica","volume":" ","pages":"1-10"},"PeriodicalIF":2.6,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142668860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Leptin and leptin receptor gene polymorphisms and depression treatment response. 瘦素和瘦素受体基因多态性与抑郁症治疗反应。
IF 2.6 4区 医学 Q3 NEUROSCIENCES Pub Date : 2024-11-12 DOI: 10.1017/neu.2024.43
Ida-Maria Tavast, Anssi Solismaa, Leo-Pekka Lyytikäinen, Nina Mononen, Eeva Moilanen, Mari Hämäläinen, Terho Lehtimäki, Olli Kampman

Objective: Associations between leptin (LEP) and leptin receptor (LEPR) gene polymorphisms and mood disorders have been found but not yet confirmed in multiple studies. The aim of our study was to study the associations between LEP and LEPR single nucleotide polymorphisms (SNPs) and treatment response of depression. Associations between leptin levels and depression severity were also investigated.

Methods: The data included 242 depressed patients in secondary psychiatric care. Symptoms of depression were assessed with the Montgomery–Åsberg Depression Rating Scale (MADRS). Previously found LEP and LEPR SNPs associated with depression and other mood disorders were studied. Furthermore, all available LEP and LEPR SNPs were clumped using proxy SNPs to represent gene areas in r2 > 0.2 linkage disequilibrium and their association with treatment response was analysed with logistic regression.

Results: Two proxy SNPs of LEPR gene, rs12564738 and rs12029311, were associated with MADRS response at 6 weeks (p adjusted = 0.024, p adjusted = 0.024). SNPs from previous studies were not associated with MADRS response, but LEPR rs12145690 from a previous study was strongly associated with rs12564738 (r2 = 0.94). The positive association between leptin levels and MADRS score at baseline after adjusting with age, sex, body mass index (BMI), Alcohol Use Disorders Identification Test score, and smoking was found (p = 0.011).

Conclusion: Our findings suggest that LEPR polymorphisms are associated with depression treatment response. We also found associations between leptin levels and depression independently of BMI. Further studies and meta-analyses are needed to confirm the significance of found SNPs and the role of leptin in depression.

目的:多项研究发现瘦素(LEP)和瘦素受体(LEPR)基因多态性与情绪障碍之间存在关联,但尚未得到证实。我们的研究旨在探讨 LEP 和 LEPR 单核苷酸多态性(SNPs)与抑郁症治疗反应之间的关系。研究还调查了瘦素水平与抑郁症严重程度之间的关系:数据包括 242 名接受二级精神病治疗的抑郁症患者。抑郁症状采用蒙哥马利-阿斯伯格抑郁评定量表(MADRS)进行评估。对之前发现的与抑郁症和其他情绪障碍相关的 LEP 和 LEPR SNPs 进行了研究。此外,还使用代理 SNP 将所有可用的 LEP 和 LEPR SNP 聚类,以代表 r2 > 0.2 连接不平衡的基因区域,并用逻辑回归分析它们与治疗反应的关系:结果:LEPR基因的两个代理SNPs rs12564738和rs12029311与6周时的MADRS反应相关(p调整后=0.024,p调整后=0.024)。先前研究中的 SNP 与 MADRS 反应无关,但先前研究中的 LEPR rs12145690 与 rs12564738 密切相关(r2 = 0.94)。在对年龄、性别、体重指数(BMI)、酒精使用障碍鉴定测试得分和吸烟进行调整后,发现瘦素水平与基线时的MADRS得分呈正相关(p = 0.011):我们的研究结果表明,LEPR 多态性与抑郁症治疗反应有关。结论:我们的研究结果表明,LEPR 多态性与抑郁症的治疗反应有关。我们还发现瘦素水平与抑郁症之间存在关联,而与体重指数无关。需要进一步的研究和荟萃分析来证实所发现的 SNPs 的重要性以及瘦素在抑郁症中的作用。
{"title":"Leptin and leptin receptor gene polymorphisms and depression treatment response.","authors":"Ida-Maria Tavast, Anssi Solismaa, Leo-Pekka Lyytikäinen, Nina Mononen, Eeva Moilanen, Mari Hämäläinen, Terho Lehtimäki, Olli Kampman","doi":"10.1017/neu.2024.43","DOIUrl":"https://doi.org/10.1017/neu.2024.43","url":null,"abstract":"<p><strong>Objective: </strong>Associations between leptin (<i>LEP</i>) and leptin receptor (<i>LEPR</i>) gene polymorphisms and mood disorders have been found but not yet confirmed in multiple studies. The aim of our study was to study the associations between <i>LEP</i> and <i>LEPR</i> single nucleotide polymorphisms (SNPs) and treatment response of depression. Associations between leptin levels and depression severity were also investigated.</p><p><strong>Methods: </strong>The data included 242 depressed patients in secondary psychiatric care. Symptoms of depression were assessed with the Montgomery–Åsberg Depression Rating Scale (MADRS). Previously found <i>LEP</i> and <i>LEPR</i> SNPs associated with depression and other mood disorders were studied. Furthermore, all available <i>LEP</i> and <i>LEPR</i> SNPs were clumped using proxy SNPs to represent gene areas in <i>r</i><sup>2</sup> > 0.2 linkage disequilibrium and their association with treatment response was analysed with logistic regression.</p><p><strong>Results: </strong>Two proxy SNPs of <i>LEPR</i> gene, rs12564738 and rs12029311, were associated with MADRS response at 6 weeks (<i>p</i> adjusted = 0.024, <i>p</i> adjusted = 0.024). SNPs from previous studies were not associated with MADRS response, but <i>LEPR</i> rs12145690 from a previous study was strongly associated with rs12564738 (<i>r</i><sup>2</sup> = 0.94). The positive association between leptin levels and MADRS score at baseline after adjusting with age, sex, body mass index (BMI), Alcohol Use Disorders Identification Test score, and smoking was found (<i>p</i> = 0.011).</p><p><strong>Conclusion: </strong>Our findings suggest that <i>LEPR</i> polymorphisms are associated with depression treatment response. We also found associations between leptin levels and depression independently of BMI. Further studies and meta-analyses are needed to confirm the significance of found SNPs and the role of leptin in depression.</p>","PeriodicalId":48964,"journal":{"name":"Acta Neuropsychiatrica","volume":" ","pages":"1-8"},"PeriodicalIF":2.6,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142631093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Use of generative artificial intelligence (AI) in psychiatry and mental health care: a systematic review. 人工智能(AI)在精神病学和精神卫生保健中的应用:系统综述。
IF 2.6 4区 医学 Q3 NEUROSCIENCES Pub Date : 2024-11-11 DOI: 10.1017/neu.2024.50
Sara Kolding, Robert M Lundin, Lasse Hansen, Søren Dinesen Østergaard

Objectives: Tools based on generative artificial intelligence (AI) such as ChatGPT have the potential to transform modern society, including the field of medicine. Due to the prominent role of language in psychiatry, e.g., for diagnostic assessment and psychotherapy, these tools may be particularly useful within this medical field. Therefore, the aim of this study was to systematically review the literature on generative AI applications in psychiatry and mental health.

Methods: We conducted a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The search was conducted across three databases, and the resulting articles were screened independently by two researchers. The content, themes, and findings of the articles were qualitatively assessed.

Results: The search and screening process resulted in the inclusion of 40 studies. The median year of publication was 2023. The themes covered in the articles were mainly mental health and well-being in general - with less emphasis on specific mental disorders (substance use disorder being the most prevalent). The majority of studies were conducted as prompt experiments, with the remaining studies comprising surveys, pilot studies, and case reports. Most studies focused on models that generate language, ChatGPT in particular.

Conclusions: Generative AI in psychiatry and mental health is a nascent but quickly expanding field. The literature mainly focuses on applications of ChatGPT, and finds that generative AI performs well, but notes that it is limited by significant safety and ethical concerns. Future research should strive to enhance transparency of methods, use experimental designs, ensure clinical relevance, and involve users/patients in the design phase.

目的:基于生成式人工智能(AI)的工具(如 ChatGPT)有可能改变现代社会,包括医学领域。由于语言在精神病学(如诊断评估和心理治疗)中的重要作用,这些工具在这一医学领域可能特别有用。因此,本研究旨在系统地综述有关生成式人工智能在精神病学和心理健康领域应用的文献:我们按照《系统综述和元分析首选报告项目》指南进行了系统综述。我们在三个数据库中进行了检索,并由两名研究人员对检索到的文章进行了独立筛选。对文章的内容、主题和结果进行了定性评估:搜索和筛选过程共纳入了 40 项研究。文章发表年份的中位数为 2023 年。文章涉及的主题主要是一般的心理健康和幸福感--较少强调特定的精神障碍(药物使用障碍最为普遍)。大多数研究都是以即时实验的形式进行的,其余研究包括调查、试点研究和病例报告。大多数研究侧重于生成语言的模型,尤其是 ChatGPT:生成式人工智能在精神病学和心理健康领域的应用刚刚起步,但发展迅速。文献主要集中在 ChatGPT 的应用上,发现生成式人工智能表现良好,但也指出其在安全性和伦理方面存在很大的局限性。未来的研究应努力提高方法的透明度,使用实验设计,确保临床相关性,并让用户/患者参与设计阶段。
{"title":"Use of generative artificial intelligence (AI) in psychiatry and mental health care: a systematic review.","authors":"Sara Kolding, Robert M Lundin, Lasse Hansen, Søren Dinesen Østergaard","doi":"10.1017/neu.2024.50","DOIUrl":"https://doi.org/10.1017/neu.2024.50","url":null,"abstract":"<p><strong>Objectives: </strong>Tools based on generative artificial intelligence (AI) such as ChatGPT have the potential to transform modern society, including the field of medicine. Due to the prominent role of language in psychiatry, e.g., for diagnostic assessment and psychotherapy, these tools may be particularly useful within this medical field. Therefore, the aim of this study was to systematically review the literature on generative AI applications in psychiatry and mental health.</p><p><strong>Methods: </strong>We conducted a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The search was conducted across three databases, and the resulting articles were screened independently by two researchers. The content, themes, and findings of the articles were qualitatively assessed.</p><p><strong>Results: </strong>The search and screening process resulted in the inclusion of 40 studies. The median year of publication was 2023. The themes covered in the articles were mainly mental health and well-being in general - with less emphasis on specific mental disorders (substance use disorder being the most prevalent). The majority of studies were conducted as prompt experiments, with the remaining studies comprising surveys, pilot studies, and case reports. Most studies focused on models that generate language, ChatGPT in particular.</p><p><strong>Conclusions: </strong>Generative AI in psychiatry and mental health is a nascent but quickly expanding field. The literature mainly focuses on applications of ChatGPT, and finds that generative AI performs well, but notes that it is limited by significant safety and ethical concerns. Future research should strive to enhance transparency of methods, use experimental designs, ensure clinical relevance, and involve users/patients in the design phase.</p>","PeriodicalId":48964,"journal":{"name":"Acta Neuropsychiatrica","volume":" ","pages":"1-14"},"PeriodicalIF":2.6,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142631105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigation of the relationship of sleep disorder occurring in fibromyalgia with central nervous system and pineal gland volume. 纤维肌痛患者睡眠障碍与中枢神经系统和松果体体积的关系研究
IF 2.6 4区 医学 Q3 NEUROSCIENCES Pub Date : 2024-11-11 DOI: 10.1017/neu.2024.49
Fatih Çiçek, İlyas Uçar, Turgut Seber, Fatma Gül Ülkü Demir, Ali Türker Çiftçi

Objective: Mechanisms of sleep disorders in fibromyalgia (FM) patients, such as insomnia, early morning awakenings and poor quality sleep, have not yet been proven and no consistent and effective treatment is yet available. The aim of this study was to investigate the pineal gland volume and the relationship between total fibre count, total fibre volume and total fibre length of the spinoreticular tract involved in regulation of sleep and wakefulness in terms of the mechanism of sleep disturbance.

Methods: This study included only female cases, 31 with fibromyalgia and 31 controls. Pittsburgh Sleep Quality Index was used to assess sleep quality. Tractography of targeted pathway from brain diffusion MR images was calculated in Diffusion Studio Imaging (DSI) Studio programme and the volume of the pineal gland was calculated in ITK-SNAP programme.

Results: The mean volume of the pineal gland was higher in control group (218.84 ± 64.45 mm3) than in fibromyalgia group (174.77 ± 48.65 mm3), which was statistically significant (p = 0.004). However, there was no statistically significant difference between two groups in total spinoreticular tract (TSRT), total volume (TSRTV), TSRT fractional anisotropy, TSRT mean diffusion, TSRT axial diffusion and TSRT radial diffusion of spinoreticular tract, which is involved in the regulation of sleep and wakefulness (p > 0.05).

Conclusion: In conclusion, it is thought that the endocrine system may be more related to sleep disturbance in individuals with FM than central nervous system. Therefore, we believe that it may be more appropriate to work on the endocrine system rather than neural system in the treatment of sleep disturbance in patients with FM.

目的:纤维肌痛(FM)患者失眠、早醒和睡眠质量差等睡眠障碍的机制尚未得到证实,也没有一致有效的治疗方法。本研究旨在从睡眠障碍的机制角度,研究松果体体积以及参与调节睡眠和觉醒的脊髓束总纤维数、总纤维体积和总纤维长度之间的关系:本研究仅包括女性病例,31 名纤维肌痛患者和 31 名对照组患者。采用匹兹堡睡眠质量指数(PSQI)评估睡眠质量。用 DSI Studio 程序计算脑弥散 MR 图像中目标通路的迹线,用 ITK-SNAP 程序计算松果体的体积:结果:对照组松果体的平均体积(218.84±64.45 mm3)高于纤维肌痛组(174.77±48.65 mm3),差异有统计学意义(P=0.004)。然而,两组在参与调节睡眠和觉醒的脊髓束总脊髓束(TSRT)、总体积(TSRTV)、TSRT FA、TSRT MD、TSRT AD和TSRT RD方面差异无统计学意义(P>0.05):总之,与中枢神经系统相比,人们认为内分泌系统可能与调频患者的睡眠障碍关系更大。因此,我们认为在治疗 FM 患者的睡眠障碍时,从内分泌系统入手可能比从神经系统入手更合适。
{"title":"Investigation of the relationship of sleep disorder occurring in fibromyalgia with central nervous system and pineal gland volume.","authors":"Fatih Çiçek, İlyas Uçar, Turgut Seber, Fatma Gül Ülkü Demir, Ali Türker Çiftçi","doi":"10.1017/neu.2024.49","DOIUrl":"10.1017/neu.2024.49","url":null,"abstract":"<p><strong>Objective: </strong>Mechanisms of sleep disorders in fibromyalgia (FM) patients, such as insomnia, early morning awakenings and poor quality sleep, have not yet been proven and no consistent and effective treatment is yet available. The aim of this study was to investigate the pineal gland volume and the relationship between total fibre count, total fibre volume and total fibre length of the spinoreticular tract involved in regulation of sleep and wakefulness in terms of the mechanism of sleep disturbance.</p><p><strong>Methods: </strong>This study included only female cases, 31 with fibromyalgia and 31 controls. Pittsburgh Sleep Quality Index was used to assess sleep quality. Tractography of targeted pathway from brain diffusion MR images was calculated in Diffusion Studio Imaging (DSI) Studio programme and the volume of the pineal gland was calculated in ITK-SNAP programme.</p><p><strong>Results: </strong>The mean volume of the pineal gland was higher in control group (218.84 ± 64.45 mm<sup>3</sup>) than in fibromyalgia group (174.77 ± 48.65 mm<sup>3</sup>), which was statistically significant (<i>p</i> = 0.004). However, there was no statistically significant difference between two groups in total spinoreticular tract (TSRT), total volume (TSRTV), TSRT fractional anisotropy, TSRT mean diffusion, TSRT axial diffusion and TSRT radial diffusion of spinoreticular tract, which is involved in the regulation of sleep and wakefulness (<i>p</i> > 0.05).</p><p><strong>Conclusion: </strong>In conclusion, it is thought that the endocrine system may be more related to sleep disturbance in individuals with FM than central nervous system. Therefore, we believe that it may be more appropriate to work on the endocrine system rather than neural system in the treatment of sleep disturbance in patients with FM.</p>","PeriodicalId":48964,"journal":{"name":"Acta Neuropsychiatrica","volume":" ","pages":"1-8"},"PeriodicalIF":2.6,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142631090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The shape of the corpus callosum is different in bipolar disorder. 躁郁症患者的胼胝体形状有所不同。
IF 2.6 4区 医学 Q3 NEUROSCIENCES Pub Date : 2024-11-06 DOI: 10.1017/neu.2024.51
Mustafa Nuray Namli, Sema Baykara, Ozlem Gul, Murat Baykara

Objective: Bipolar disorder (BD) is a recurrent chronic disorder characterised by fluctuations in mood and energy disposition. Diseases could lead to degenerative alterations in brain structures such as corpus callosum (CC). Studies demonstrated that abnormalities in CC are associated with BD symptoms. The present study aims to analyse the CC of the patients with statistical shape analysis (SSA) and compare the findings with healthy controls.

Methods: Forty-one BD patients and 41 healthy individuals in similar age groups, which included 23 female and 18 male subjects, participated in the study. CC was marked with landmarks on the mid-sagittal images of each individual. The mean 'Procrustes' point was calculated, and shape deformations were analysed with thin-plate spline analysis.

Results: Significant differences were observed in the shape of CC between the two groups, where maximum CC deformation was observed in posterior region marks in BD patients. There was no significant difference between the CC area of the BD patients and controls.

Conclusions: CC analysis conducted with SSA revealed significant differences between patients and healthy controls. The study findings emphasised the abnormal distribution of white matter in CC and the variable subregional nature of CC in BD patients. This study may enable the development of more targeted and effective treatment strategies by taking into account biological factors and understanding the differences in the brain regions of individuals with BD.

目的:躁郁症(BD)是一种反复发作的慢性疾病,以情绪和精力波动为特征。疾病可导致大脑结构(如胼胝体)发生退行性改变。研究表明,CC 的异常与 BD 症状有关。本研究旨在通过统计形状分析(SSA)对患者的 CC 进行分析,并将结果与健康对照组进行比较:方法:41 名 BD 患者和 41 名年龄相仿的健康人参加了研究,其中包括 23 名女性和 18 名男性受试者。在每个人的中矢状面图像上用地标标记 CC。计算 "Procrustes "点的平均值,并用薄板样条分析法对形状变形进行分析:结果:观察到两组患者的CC形状存在显著差异,其中BD患者后部标记处的CC变形最大。BD患者的CC面积与对照组无明显差异:结论:使用 SSA 进行的 CC 分析显示,患者与健康对照组之间存在显著差异。研究结果强调了白质在CC中的异常分布以及BD患者CC亚区域的可变性。这项研究可通过考虑生物学因素和了解 BD 患者大脑区域的差异,制定更有针对性和更有效的治疗策略。
{"title":"The shape of the corpus callosum is different in bipolar disorder.","authors":"Mustafa Nuray Namli, Sema Baykara, Ozlem Gul, Murat Baykara","doi":"10.1017/neu.2024.51","DOIUrl":"https://doi.org/10.1017/neu.2024.51","url":null,"abstract":"<p><strong>Objective: </strong>Bipolar disorder (BD) is a recurrent chronic disorder characterised by fluctuations in mood and energy disposition. Diseases could lead to degenerative alterations in brain structures such as corpus callosum (CC). Studies demonstrated that abnormalities in CC are associated with BD symptoms. The present study aims to analyse the CC of the patients with statistical shape analysis (SSA) and compare the findings with healthy controls.</p><p><strong>Methods: </strong>Forty-one BD patients and 41 healthy individuals in similar age groups, which included 23 female and 18 male subjects, participated in the study. CC was marked with landmarks on the mid-sagittal images of each individual. The mean 'Procrustes' point was calculated, and shape deformations were analysed with thin-plate spline analysis.</p><p><strong>Results: </strong>Significant differences were observed in the shape of CC between the two groups, where maximum CC deformation was observed in posterior region marks in BD patients. There was no significant difference between the CC area of the BD patients and controls.</p><p><strong>Conclusions: </strong>CC analysis conducted with SSA revealed significant differences between patients and healthy controls. The study findings emphasised the abnormal distribution of white matter in CC and the variable subregional nature of CC in BD patients. This study may enable the development of more targeted and effective treatment strategies by taking into account biological factors and understanding the differences in the brain regions of individuals with BD.</p>","PeriodicalId":48964,"journal":{"name":"Acta Neuropsychiatrica","volume":" ","pages":"1-7"},"PeriodicalIF":2.6,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142584765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relationship between early traumatic experiences and emotional regulation skills in major depressive and bipolar disorders. 重度抑郁症和双相情感障碍患者的早期创伤经历与情绪调节能力之间的关系。
IF 2.6 4区 医学 Q3 NEUROSCIENCES Pub Date : 2024-10-28 DOI: 10.1017/neu.2024.41
Yejin Park, Chan Woo Lee, Yoonjeong Jang, Sarah Soonji Kwon, Hyeona Yu, Joohyun Yoon, Yun Seong Park, Hyun A Ryoo, Junwoo Jang, Hyuk Joon Lee, Yeong Chan Lee, Hong-Hee Won, Tae Hyon Ha, Woojae Myung

Childhood trauma can cause deficits in emotional regulation. However, few studies have investigated childhood trauma and emotional regulation skills in patients with mood disorders. We aimed to investigate how childhood trauma and Emotion Regulation Skills Questionnaire (ERSQ) scores are associated with mood disorders.This study included 779 patients with mood disorders (major depressive disorder [MDD, n = 240], bipolar I disorder [BDI, n = 121], and bipolar II disorder [BDII, n = 418]). We used their Childhood Trauma Questionnaire-Short Form (CTQ) and ERSQ scores for the evaluation.The between-group differences in CTQ and ERSQ scores were examined. The CTQ and ERSQ total scores were negatively correlated. Among the CTQ subscales, emotional neglect showed a significant correlation with the ERSQ total score, whereas acceptance and tolerance showed higher negative correlations with the CTQ than with the other ERSQ subscales. The negative relationship between emotional regulation and childhood trauma varied significantly depending on the group, with the BDI group showing a more prominent association than the other groups.Based on various mood disorders, we observed associations between childhood trauma and emotional regulation skills. Consequently, our study offers notable insights for future research on the impact of childhood trauma on ERSQ.

童年创伤可导致情绪调节能力的缺陷。然而,很少有研究对情绪障碍患者的童年创伤和情绪调节能力进行调查。本研究纳入了 779 名情绪障碍患者(重度抑郁障碍 [MDD,n = 240]、双相情感障碍 I [BDI,n = 121]和双相情感障碍 II [BDII,n = 418])。我们使用他们的童年创伤问卷-短表(CTQ)和 ERSQ 分数进行评估。CTQ 和 ERSQ 的总分呈负相关。在 CTQ 各分量表中,情绪忽视与 ERSQ 总分呈显著相关,而接纳和宽容与 CTQ 的负相关高于 ERSQ 的其他分量表。情绪调节与童年创伤之间的负相关在不同组别之间存在明显差异,BDI 组比其他组别表现出更突出的相关性。因此,我们的研究为今后研究童年创伤对 ERSQ 的影响提供了重要启示。
{"title":"Relationship between early traumatic experiences and emotional regulation skills in major depressive and bipolar disorders.","authors":"Yejin Park, Chan Woo Lee, Yoonjeong Jang, Sarah Soonji Kwon, Hyeona Yu, Joohyun Yoon, Yun Seong Park, Hyun A Ryoo, Junwoo Jang, Hyuk Joon Lee, Yeong Chan Lee, Hong-Hee Won, Tae Hyon Ha, Woojae Myung","doi":"10.1017/neu.2024.41","DOIUrl":"https://doi.org/10.1017/neu.2024.41","url":null,"abstract":"<p><p>Childhood trauma can cause deficits in emotional regulation. However, few studies have investigated childhood trauma and emotional regulation skills in patients with mood disorders. We aimed to investigate how childhood trauma and Emotion Regulation Skills Questionnaire (ERSQ) scores are associated with mood disorders.This study included 779 patients with mood disorders (major depressive disorder [MDD, <i>n</i> = 240], bipolar I disorder [BDI, <i>n</i> = 121], and bipolar II disorder [BDII, <i>n</i> = 418]). We used their Childhood Trauma Questionnaire-Short Form (CTQ) and ERSQ scores for the evaluation.The between-group differences in CTQ and ERSQ scores were examined. The CTQ and ERSQ total scores were negatively correlated. Among the CTQ subscales, emotional neglect showed a significant correlation with the ERSQ total score, whereas acceptance and tolerance showed higher negative correlations with the CTQ than with the other ERSQ subscales. The negative relationship between emotional regulation and childhood trauma varied significantly depending on the group, with the BDI group showing a more prominent association than the other groups.Based on various mood disorders, we observed associations between childhood trauma and emotional regulation skills. Consequently, our study offers notable insights for future research on the impact of childhood trauma on ERSQ.</p>","PeriodicalId":48964,"journal":{"name":"Acta Neuropsychiatrica","volume":" ","pages":"1-9"},"PeriodicalIF":2.6,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142511081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anxiolytic-like effects of acute serotonin-releasing agents in zebrafish models of anxiety: experimental study and systematic review. 急性血清素释放剂对斑马鱼焦虑模型的类似抗焦虑作用:实验研究和系统综述。
IF 2.6 4区 医学 Q3 NEUROSCIENCES Pub Date : 2024-10-28 DOI: 10.1017/neu.2024.44
Jakob Näslund, Jenny Landin, Fredrik Hieronymus, Rakesh Kumar Banote, Petronella Kettunen

Though commonly used to model affective disorders, zebrafish display notable differences in terms of the structure and function of the brain serotonin system, including responses to pharmacological interventions, as compared to mammals. For example, elevation of brain serotonin following acute administration of serotonin reuptake inhibitors (SRIs) generally has anxiogenic effects, both in the clinical situation and in rodent models of anxiety, but previous research has indicated the opposite in zebrafish. However, several issues remain unresolved. We conducted a systematic review of SRI effects in zebrafish models of anxiety and, on the basis of these results, performed a series of experiments further investigating the influence of serotonin-releasing agents on anxiety-like behaviour in zebrafish, with sex-segregated wild-type animals being administered either escitalopram, or the serotonin releaser fenfluramine, in the light-dark test. In the systematic review, we find that the available literature indicates an anxiolytic-like effect of SRIs in the novel-tank diving test. Regarding the light-dark test, most studies reported no behavioural effects of SRIs, although the few that did generally saw anxiolytic-like responses. In the experimental studies, consistent anxiolytic-like effects were observed with neither sex nor habituation influencing treatment response. We find that the general effect of acute SRI administration in zebrafish indeed appears to be anxiolytic-like, indicating, at least partly, differences in the functioning of the serotonin system as compared to mammals and that caution is advised when using zebrafish to model affective disorders.

尽管斑马鱼通常被用来模拟情感障碍,但与哺乳动物相比,斑马鱼在大脑血清素系统的结构和功能方面(包括对药物干预的反应)存在明显差异。例如,在临床和啮齿动物焦虑模型中,急性服用血清素再摄取抑制剂(SRIs)后脑血清素的升高通常会产生焦虑效应,但之前的研究表明斑马鱼的情况恰恰相反。然而,有几个问题仍未解决。我们对 SRI 在斑马鱼焦虑模型中的影响进行了系统回顾,并在这些结果的基础上进行了一系列实验,进一步研究血清素释放药对斑马鱼焦虑样行为的影响。在系统综述中,我们发现现有文献表明,SRIs 在新水槽潜水试验中具有类似抗焦虑的效果。关于光-暗试验,大多数研究报告称 SRIs 没有行为效应,尽管少数报告称 SRIs 一般会产生类似抗焦虑的反应。在实验研究中,观察到了一致的抗焦虑效应,性别和习惯都不会影响治疗反应。我们发现,在斑马鱼中急性服用 SRI 的一般效果似乎确实是抗焦虑样的,这至少部分表明,与哺乳动物相比,斑马鱼的血清素系统功能存在差异,因此在使用斑马鱼来模拟情感障碍时应谨慎。
{"title":"Anxiolytic-like effects of acute serotonin-releasing agents in zebrafish models of anxiety: experimental study and systematic review.","authors":"Jakob Näslund, Jenny Landin, Fredrik Hieronymus, Rakesh Kumar Banote, Petronella Kettunen","doi":"10.1017/neu.2024.44","DOIUrl":"https://doi.org/10.1017/neu.2024.44","url":null,"abstract":"<p><p>Though commonly used to model affective disorders, zebrafish display notable differences in terms of the structure and function of the brain serotonin system, including responses to pharmacological interventions, as compared to mammals. For example, elevation of brain serotonin following acute administration of serotonin reuptake inhibitors (SRIs) generally has anxiogenic effects, both in the clinical situation and in rodent models of anxiety, but previous research has indicated the opposite in zebrafish. However, several issues remain unresolved. We conducted a systematic review of SRI effects in zebrafish models of anxiety and, on the basis of these results, performed a series of experiments further investigating the influence of serotonin-releasing agents on anxiety-like behaviour in zebrafish, with sex-segregated wild-type animals being administered either escitalopram, or the serotonin releaser fenfluramine, in the light-dark test. In the systematic review, we find that the available literature indicates an anxiolytic-like effect of SRIs in the novel-tank diving test. Regarding the light-dark test, most studies reported no behavioural effects of SRIs, although the few that did generally saw anxiolytic-like responses. In the experimental studies, consistent anxiolytic-like effects were observed with neither sex nor habituation influencing treatment response. We find that the general effect of acute SRI administration in zebrafish indeed appears to be anxiolytic-like, indicating, at least partly, differences in the functioning of the serotonin system as compared to mammals and that caution is advised when using zebrafish to model affective disorders.</p>","PeriodicalId":48964,"journal":{"name":"Acta Neuropsychiatrica","volume":" ","pages":"1-19"},"PeriodicalIF":2.6,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142511080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring the potential link between ΔFosB and N-acetylcysteine in craving/relapse dynamics: can N-acetylcysteine stand out as a possible treatment candidate? 探索ΔFosB和N-乙酰半胱氨酸在渴求/复发动态中的潜在联系:N-乙酰半胱氨酸能否作为一种可能的候选治疗药物脱颖而出?
IF 2.6 4区 医学 Q3 NEUROSCIENCES Pub Date : 2024-10-17 DOI: 10.1017/neu.2024.38
Shokouh Arjmand, Mehran Ilaghi, Mohammad Shafie'ei, Pedro H Gobira, Rodrigo Grassi-Oliveira, Gregers Wegener

From a neuroscientific point of view, one of the unique archetypes of substance use disorders is its road to relapse, in which the reward system plays a crucial role. Studies on the neurobiology of substance use disorders have highlighted the central role of a protein belonging to the Fos family of transcription factors, ΔFosB. Relying on the roles ΔFosB plays in the pathophysiology of substance use disorders, we endeavour to present some evidence demonstrating that N-acetylcysteine, a low-cost and well-tolerated over-the-counter medicine, may influence the downstream pathway of ΔFosB, thereby serving as a treatment strategy to mitigate the risk of relapse in cases of substance use.

从神经科学的角度来看,药物滥用症的一个独特原型是其复发之路,而奖赏系统在其中扮演着至关重要的角色。对药物使用障碍的神经生物学研究强调了一种属于转录因子 Fos 家族的蛋白质 ΔFosB 的核心作用。根据ΔFosB在药物使用障碍的病理生理学中所起的作用,我们试图提出一些证据,证明N-乙酰半胱氨酸这种成本低、耐受性好的非处方药物可能会影响ΔFosB的下游通路,从而作为一种治疗策略,降低药物使用病例的复发风险。
{"title":"Exploring the potential link between ΔFosB and <i>N</i>-acetylcysteine in craving/relapse dynamics: can <i>N</i>-acetylcysteine stand out as a possible treatment candidate?","authors":"Shokouh Arjmand, Mehran Ilaghi, Mohammad Shafie'ei, Pedro H Gobira, Rodrigo Grassi-Oliveira, Gregers Wegener","doi":"10.1017/neu.2024.38","DOIUrl":"https://doi.org/10.1017/neu.2024.38","url":null,"abstract":"<p><p>From a neuroscientific point of view, one of the unique archetypes of substance use disorders is its road to relapse, in which the reward system plays a crucial role. Studies on the neurobiology of substance use disorders have highlighted the central role of a protein belonging to the Fos family of transcription factors, ΔFosB. Relying on the roles ΔFosB plays in the pathophysiology of substance use disorders, we endeavour to present some evidence demonstrating that <i>N</i>-acetylcysteine, a low-cost and well-tolerated over-the-counter medicine, may influence the downstream pathway of ΔFosB, thereby serving as a treatment strategy to mitigate the risk of relapse in cases of substance use.</p>","PeriodicalId":48964,"journal":{"name":"Acta Neuropsychiatrica","volume":" ","pages":"1-14"},"PeriodicalIF":2.6,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142478561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Acta Neuropsychiatrica
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1